USA - NASDAQ:ICUI - US44930G1076 - Common Stock
The current stock price of ICUI is 142.34 USD. In the past month the price increased by 15.27%. In the past year, price decreased by -15.51%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| COO | COOPER COS INC/THE | 18.77 | 15.00B | ||
| SOLV | SOLVENTUM CORP | 13.96 | 14.37B | ||
| ALGN | ALIGN TECHNOLOGY INC | 14.74 | 10.33B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 23.44 | 5.16B | ||
| LNTH | LANTHEUS HOLDINGS INC | 9.37 | 3.80B | ||
| HAE | HAEMONETICS CORP/MASS | 16.41 | 3.80B | ||
| XRAY | DENTSPLY SIRONA INC | 6.7 | 2.11B | ||
| UFPT | UFP TECHNOLOGIES INC | 25.49 | 1.70B | ||
| STAA | STAAR SURGICAL CO | N/A | 1.38B | ||
| NEOG | NEOGEN CORP | 19.07 | 1.24B | ||
| EMBC | EMBECTA CORP | 4.99 | 852.20M | ||
| BVS | BIOVENTUS INC - A | 12.27 | 598.60M |
ICU Medical, Inc. engages in the provision of innovative medical products used in infusion therapy and critical care applications. The company is headquartered in San Clemente, California and currently employs 15,000 full-time employees. Its product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needlefree IV connectors, peripheral IV catheters, and sterile IV solutions; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products. Its Infusion Therapy products include Clave needlefree products, Neutron, ClearGuard, and Tego. Its oncology products include ChemoLock Closed System Transfer Devices (CSTD) and Deltec GRIPPER non-coring needles for portal access. Its vascular access products include Safe-T Wing venipuncture and blood collection devices; Port-A-Cath implantable port, and Portex arterial blood sampling syringes. Its Tracheostomy products include Portex BLUselect PVC tracheostomy tubes.
ICU MEDICAL INC
951 Calle Amanecer
San Clemente CALIFORNIA 92763 US
CEO: Vivek Jain
Employees: 15000
Phone: 19493662183
ICU Medical, Inc. engages in the provision of innovative medical products used in infusion therapy and critical care applications. The company is headquartered in San Clemente, California and currently employs 15,000 full-time employees. Its product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needlefree IV connectors, peripheral IV catheters, and sterile IV solutions; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products. Its Infusion Therapy products include Clave needlefree products, Neutron, ClearGuard, and Tego. Its oncology products include ChemoLock Closed System Transfer Devices (CSTD) and Deltec GRIPPER non-coring needles for portal access. Its vascular access products include Safe-T Wing venipuncture and blood collection devices; Port-A-Cath implantable port, and Portex arterial blood sampling syringes. Its Tracheostomy products include Portex BLUselect PVC tracheostomy tubes.
The current stock price of ICUI is 142.34 USD. The price increased by 5.96% in the last trading session.
ICUI does not pay a dividend.
ICUI has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
12 analysts have analysed ICUI and the average price target is 177.68 USD. This implies a price increase of 24.83% is expected in the next year compared to the current price of 142.34.
ICU MEDICAL INC (ICUI) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
ICU MEDICAL INC (ICUI) has a market capitalization of 3.51B USD. This makes ICUI a Mid Cap stock.
ChartMill assigns a technical rating of 8 / 10 to ICUI. When comparing the yearly performance of all stocks, ICUI turns out to be only a medium performer in the overall market: it outperformed 42.3% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to ICUI. Both the profitability and the financial health of ICUI get a neutral evaluation. Nothing too spectacular is happening here.
Over the last trailing twelve months ICUI reported a non-GAAP Earnings per Share(EPS) of 7.96. The EPS increased by 40.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.9% | ||
| ROE | -1.75% | ||
| Debt/Equity | 0.63 |
12 analysts have analysed ICUI and the average price target is 177.68 USD. This implies a price increase of 24.83% is expected in the next year compared to the current price of 142.34.
For the next year, analysts expect an EPS growth of 14.6% and a revenue growth -5.53% for ICUI